表紙
市場調查報告書

無菌注射劑委託製造外包(CMO)的全球市場:以產品種類 應用、分子、容器區分的預測(2020年∼2030年)與主要企業的概要資訊

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030: Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors), Application, Molecule, Container, Profiling of Major Players

出版商 Visiongain Ltd 商品編碼 940971
出版日期 內容資訊 英文 161 Pages
商品交期: 最快1-2個工作天內
價格
無菌注射劑委託製造外包(CMO)的全球市場:以產品種類 應用、分子、容器區分的預測(2020年∼2030年)與主要企業的概要資訊 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030: Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors), Application, Molecule, Container, Profiling of Major Players
出版日期: 2020年05月01日內容資訊: 英文 161 Pages
簡介

本報告是針對全球的無菌注射劑委託製造外包(CMO)市場調查分析並包括市場概要、分類的收益預估、以國家地區區別的市場分析、主要企業等,提供完整有體系的情報資訊。

目錄

第1章 全球無菌注射劑CMO市場 2020-2030

  • 執行摘要
  • 本報告的價值
  • 本報告提供的內容
  • 主要問答
  • 本報告的對象讀者
  • 調查方法
  • 常見問題(FAQ)
  • 相關報告
  • 關於Visiongain

第2章 無菌注射劑CMO市場導論

  • 無菌注射劑CMO的機會
  • 無菌注射劑CMO的定義
    • CMO的定義
  • 無菌注射劑CMO分段
    • 執行摘要
    • 段落
    • 單克隆抗體
    • 胰島素
    • 細胞因子
    • 疫苗
    • 血液因子
    • 糖尿病
    • 心血管疾病
    • CNS
    • 傳染病
    • 小分子
    • 大分子
    • 瓶子
    • 安瓿
    • 小瓶
    • 預裝注射器

第3章 市場概要

  • 市場成長因素
    • 慢性病患病率上升
    • 對生物製劑的有利需求
    • 2022年為止的專利懸崖
  • 阻礙市場因素
    • 嚴格的規定
  • 市場機會
    • 新興業務部門與經濟
  • 五力分析

第4章 以產品種類區別的市場

  • 單克隆抗體子市場預測2020-2030
  • 胰島素子市場預測2020-2030
  • 細胞因子子市場預測2020-2030
  • 疫苗子市場預測2020-2030
  • 血液因子子市場預測2020-2030

第5章 以應用區別的市場

  • 癌子市場預測2020-2030年
  • 糖尿病子市場預測2020-2030
  • 心血管疾病子市場預測2020-2030
  • CNS子市場預測2020-2030
  • 傳染病子市場預測2020-2030
  • 其他子市場預測2020-2030

第6章 以分子區別的市場

  • 小分子子市場預測2020-2030
  • 大分子子市場預測2020-2030

第7章 以容器區別的市場

  • 瓶子子市場預測2020-2030
  • 安瓿子市場預測2020-2030
  • 小瓶子市場預測2020-2030
  • 預裝注射器子市場預測2020-2030
  • 盒子市場預測2020-2030

第8章 以地區與主要國家區別預測測(2020年到2030年)

  • 以國家區別市場份額預測 2020-2030年
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他國家
  • 亞太地區
    • 中國
    • 日本
    • 印度CMO
    • 亞太地區其他國家
  • 拉丁美洲
  • 中東與非洲

第9章 龍頭企業

  • Jubilant Life Sciences Limited
  • Boehringer Ingelheim
  • Pfizer CentreOne
  • Baxter Biopharma Solutions
  • Recipharm AB
  • Lonza
  • Famar Health Care Services
  • Patheon, Inc (Parent organization: Thermo Fischer company)
  • Catalent, Inc
  • Almac Group
  • Evonik Industries AG
  • Siegfried Holding AG
  • Consort Medical, Plc
  • Aenova Group
  • Grifols SA

第10章 結論與提議

  • 相關Visiongain報告
    • 訂購格式

第11章 附錄A

  • 關於Visiongain
    • 附錄B
  • Visiongain評定格式
目錄
Product Code: PHA0737

Title:
Contract Manufacturing Outsourcing (CMO) of
Sterile Injectable Drugs Market Report 2020-2030

Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors, Others), Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), Molecule (Small Molecule and Large Molecule), Container (Bottles, Ampoules, Vials, Bags, Pre-filled Syringes, Others) Plus Company Profiling of Major Players.

Our 161-page report provides 77 tables, 75 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing CMO of sterile injectable drugs market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter's Five Forces Analysis, product profiles and commercial developments.

Discover sales predictions for the global market and submarkets

Along with revenue prediction for the overall world market, there are 4 segmentations of the CMO of sterile injectable drugs market, with forecasts for 5 product types, 6 applications, 2 molecules, 5 containers each forecasted at a global and regional level.

Global CMO of Sterile Injectable Drugs Market by Product Type

  • Monoclonal antibodies
  • Insulin
  • Cytokines
  • Vaccines
  • Blood factors
  • Others

Global CMO of Sterile Injectable Drugs Market by Application

  • Cancer
  • Diabetes
  • Cardiovascular diseases
  • CNS
  • Infectious
  • Others

Global CMO of Sterile Injectable Drugs Market by Molecule

  • Large Molecule
  • Small Molecule

Global CMO of Sterile Injectable Drugs Market by Container

  • Bottles
  • Ampoules
  • Vials
  • Prefilled syringes
  • Bags

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

  • North America:
    • US
    • Canada
  • Europe:
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific:
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Latin America
  • Middle East & Africa

Leading Companies covered in the report include:

  • Jubilant Life Sciences Limited
  • Boehringer Ingelheim
  • Pfizer CentreOne
  • Baxter Biopharma Solutions
  • Recipharm AB
  • Lonza
  • Famar Health Care Services
  • Patheon, Inc (Parent organization: Thermo Fischer company)
  • Catalent, Inc
  • Almac Group
  • Evonik Industries AG
  • Siegfried Holding AG
  • Consort Medical, Plc.
  • Aenova Group
  • Grifols SA

The report also includes profiles and for some of the leading companies in the CMO of sterile injectable drugs market, with a focus on this segment of these companies' operations:

  • Famar Health Care Services
  • Boehringer Ingelheim
  • Baxter Biopharma Solutions
  • Lonza
  • Jubilant Life Sciences Limited

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Japan, India and China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth

Overall world revenue for CMO of sterile injectable drugs will surpass US$55.33 billion by 2030, our work calculates. We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the CMO of Sterile Injectable Drugs Market report helps you

In summary, our 160 pages report provides you with the following knowledge:

  • Revenue forecasts to 2030 for 4 segmentations of the CMO of Sterile Injectable Drugs market, with forecasts for 5 product types, 6 applications, 2 molecules, 5 containers, each forecasted at a global and regional level-discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2030 for 5 regional and 11 key national markets - See forecasts for the CMO of Sterile Injectable Drugs market in North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.
  • Drivers, Restraints, Challenges, Opportunities
  • Porter's Five Forces Analysis
  • Prospects for established firms and those seeking to enter the market- including company profiles for 15 of the major companies involved in the CMO of sterile injectable drugs market
  • Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain study is for everybody needing commercial analyses for the CMO of Sterile Injectable Drugs market and leading companies. You will find data, trends and predictions.

Get our report today Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2020-2030: Forecasts by Product Type (Monoclonal Antibodies, Insulin, Cytokines, Vaccines, Blood Factors, Others), Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), Molecule (Small Molecule and Large Molecule), Container (Bottles, Ampoules, Vials, Bags, Pre-filled Syringes, Others) Plus Company Profiling of Major Players.

Table of Contents

1. Global CMO of Sterile Injectable Drugs Market 2020-2030

  • 1.1. Executive Summary
  • 1.2. Why You Should Read This Report
  • 1.3. What This Report Delivers
  • 1.4. Key Questions Answered by This Analytical Report Include:
  • 1.5. Who is This Report For?
  • 1.6. Methodology
  • 1.7. Frequently Asked Questions (FAQs)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to the CMO of Sterile Injectable Drugs Market

  • 2.1. Opportunities for the CMO of sterile injectable:
  • 2.2. CMO of Sterile Injectable Definition
    • 2.2.1. Contract Manufacturing Definition
  • 2.3. CMO of sterile injectable Segmentation
    • 2.3.1. CMO of sterile injectable executive summary
    • 2.3.2. CMO of sterile injectable Segmentation
    • 2.3.3. Monoclonal antibodies
    • 2.3.4. Insulin
    • 2.3.5. Cytokines
    • 2.3.6. Vaccines
    • 2.3.7. Blood factors
    • 2.3.8. Cancer
    • 2.3.9. Diabetes
    • 2.3.10. Cardiovascular diseases
    • 2.3.11. CNS
    • 2.3.12. Infectious
    • 2.3.13. Small molecules
    • 2.3.14. Large molecules
    • 2.3.15. Bottles
    • 2.3.16. Ampoules
    • 2.3.17. Vials
    • 2.3.18. Prefilled syringes
    • 2.3.19. Bags

3. Market Overview

  • 3.1. Market Drivers
    • 3.1.1. Increasing Prevalence of Chronic Diseases
    • 3.1.2. Lucrative demand for biologics
    • 3.1.3. Patent Cliff Till 2022
  • 3.2. Market Restraints
    • 3.2.1. Stringent Regulatory Requirements
  • 3.3. Market Opportunities
    • 3.3.1. Emerging Business Segments and Economies
  • 3.4. Porter's five forces
    • 3.4.1. Bargaining Power of Buyers
    • 3.4.2. Bargaining Power of Suppliers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Industry Rivalry

4. Global CMO of Sterile Injectable Drugs Market by Product Type

  • 4.1. Monoclonal antibodies Submarket Forecast 2020-2030
  • 4.2. Insulin Submarket Forecast 2020-2030
  • 4.3. Cytokines Submarket Forecast 2020-2030
  • 4.4. Vaccines Submarket Forecast 2020-2030
  • 4.5. Blood factors Submarket Forecast 2020-2030

5. Global CMO of Sterile Injectable Drugs Market by Application

  • 5.1. Cancer Submarket Forecast 2020-2030
  • 5.2. Diabetes Submarket Forecast 2020-2030
  • 5.3. Cardiovascular diseases Submarket Forecast 2020-2030
  • 5.4. CNS Submarket Forecast 2020-2030
  • 5.5. Infectious Submarket Forecast 2020-2030
  • 5.6. Others Submarket Forecast 2020-2030

6. Global CMO of Sterile Injectable Drugs Market by Molecule

  • 6.1. Small Molecule Submarket Forecast 2020-2030
  • 6.2. Large Molecule Submarket Forecast 2020-2030

7. Global CMO of Sterile Injectable Drugs Market by Container

  • 7.1. Bottles Submarket Forecast 2020-2030
  • 7.2. Ampoules Submarket Forecast 2020-2030
  • 7.3. Vials Submarket Forecast 2020-2030
  • 7.4. Prefilled Syringe Submarket Forecast 2020-2030
  • 7.5. Bags Submarket Forecast 2020-2030

8. Regional and Leading National CMO of sterile injectable Forecasts 2020-2030

  • 8.1. Global CMO of sterile injectable by National Market Share Forecast 2020-2030
  • 8.2. North America CMO of sterile injectable Forecast 2020-2030
    • 8.2.1. U.S. CMO of Sterile Injectable Forecast 2020-2030
    • 8.2.2. Canada CMO of sterile injectable Forecast 2020-2030
  • 8.3. Europe CMO of sterile injectable Forecast 2020-2030
    • 8.3.1. Germany CMO of sterile injectable Forecast 2020-2030
    • 8.3.2. France CMO of sterile injectable Forecast 2020-2030
    • 8.3.3. UK CMO of sterile injectable Forecast 2020-2030
    • 8.3.4. Italy CMO of Sterile Injectable Forecast 2020-2030
    • 8.3.5. Spain CMO of sterile injectable Forecast 2020-2030
    • 8.3.6. Rest of Europe CMO of sterile injectable Forecast 2020-2030
  • 8.4. Asia Pacific CMO of sterile injectable Forecast 2020-2030
    • 8.4.1. China CMO of sterile injectable Forecast 2020-2030
    • 8.4.2. Japan CMO of sterile injectable Forecast 2020-2030
    • 8.4.3. India CMO of sterile injectable Forecast 2020-2030
    • 8.4.4. Rest of APAC CMO of sterile injectable Forecast 2020-2030
  • 8.5. Latin America CMO of sterile injectable Forecast 2020-2030
  • 8.6. Middle East & Africa CMO of sterile injectable Forecast 2020-2030

9. Leading Companies in the CMO of sterile injectable

  • 9.1. Jubilant Life Sciences Limited
    • 9.1.1. Jubilant Life Sciences Limited Total Company Sales 2016-2019
    • 9.1.2. Jubilant Life Sciences Limited Products / Services
    • 9.1.3. Jubilant Life Sciences Limited Mergers & Acquisitions (M&A) Activity
  • 9.2. Boehringer Ingelheim
    • 9.2.1. Boehringer Ingelheim Total Company Sales 2016-2018
    • 9.2.2. Boehringer Ingelheim Products / Services
    • 9.2.3. Boehringer Ingelheim Mergers & Acquisitions (M&A) Activity
  • 9.3. Pfizer CentreOne
    • 9.3.1. Pfizer CentreOne Total Company Sales 2016-2019
    • 9.3.2. Pfizer CentreOne Products / Services
    • 9.3.3. Pfizer CentreOne Mergers & Acquisitions (M&A) Activity
  • 9.4. Baxter Biopharma Solutions
    • 9.4.1. Baxter Biopharma Solutions Total Company Sales 2016-2019
    • 9.4.2. Baxter Biopharma Solutions Products / Services
    • 9.4.3. Baxter Biopharma Mergers & Acquisitions (M&A) Activity
  • 9.5. Recipharm AB
    • 9.5.1. Recipharm AB Total Company Sales 2016-2018
    • 9.5.2. Recipharm AB Products / Services
    • 9.5.3. Recipharm AB Mergers & Acquisitions (M&A) Activity
  • 9.6. Lonza
    • 9.6.1. Lonza Total Company Sales 2016-2019
    • 9.6.2. Lonza Products / Services
    • 9.6.3. Lonza Mergers & Acquisitions (M&A) Activity
  • 9.7. Famar Health Care Services
    • 9.7.1. Famar Health Care Services Products / Services
    • 9.7.2. Famar Health Care Services Mergers & Acquisitions (M&A) Activity
  • 9.8. Patheon, Inc (Parent organization: Thermo Fischer company)
    • 9.8.1. Patheon, Inc Total Company Sales 2016-2018
    • 9.8.2. Patheon, Inc Products / Services
    • 9.8.3. Patheon, Inc Mergers & Acquisitions (M&A) Activity
  • 9.9. Catalent, Inc
    • 9.9.1. Catalent, Inc Total Company Sales 2016-2019
    • 9.9.2. Catalent, Inc . Products / Services
    • 9.9.3. Catalent, Inc . Mergers & Acquisitions (M&A) Activity
  • 9.10. Almac Group
    • 9.10.1. Almac Group Total Company Sales 2018
    • 9.10.2. Almac Group Products / Services
    • 9.10.3. Almac Group Mergers & Acquisitions (M&A) Activity
  • 9.11. Evonik Industries AG
    • 9.11.1. Evonik Industries AG Total Company Sales 2016-2019
    • 9.11.2. Evonik Industries AG Products / Services
    • 9.11.3. Evonik Industries AG Mergers & Acquisitions (M&A) Activity
  • 9.12. Siegfried Holding AG
    • 9.12.1. Siegfried Holding AG Total Company Sales 2016-2019
    • 9.12.2. Siegfried Holding AG Products / Services
    • 9.12.3. Siegfried Holding AG Mergers & Acquisitions (M&A) Activity
  • 9.13. Consort Medical, Plc
    • 9.13.1. Consort Medical, Plc. Total Company Sales 2016-2019
    • 9.13.2. Consort Medical, Plc. Products / Services
    • 9.13.3. Consort Medical, Plc. Mergers & Acquisitions (M&A) Activity
  • 9.14. Aenova Group
    • 9.14.1. Aenova GroupProducts / Services
  • 9.15. Grifols SA
    • 9.15.1. Grifols SA Total Company Sales 2016-2019
    • 9.15.2. Grifols SA Products / Services
    • 9.15.3. Grifols SA Mergers & Acquisitions (M&A) Activity

10. Conclusions and Recommendations

  • 10.1. Associated Visiongain Reports
    • Visiongain Report Sales Order Form

11. Appendix A

  • 11.1. About Visiongain
    • Appendix B
  • 11.2. Visiongain report evaluation form

List of Tables

  • Table 1. Executive Summary
  • Table 2. CVD Total Costs Through 2035
  • Table 3. HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline
    • Agent
    • Class/Type
    • Trial Registry Identifier(s)
    • Manufacturer/ Sponsor
    • Status
    • Ad26.Mos4.HIV, clade C and mosaic gp140 HIV/ alum
    • Ad26 vectors encoding four mosaic Env, Gag, and Pol antigens (Ad26.Mos1.Gag-Pol, Ad26. Mos2.Gag-Pol, Ad26.Mos1.Env, Ad26.Mos2S.Env) Clade C and mosaic gp140 protein in alum adjuvant ............................................................................................................................................... 35 NCT03964415 (HPX3002/ HVTN 706) ................................................................................................ 35 Janssen Vaccines & Prevention B.V ................................................................................................... 35 Phase III ............................................................................................................................................... 35 ALVAC-HIV (vCP2438), bivalent clade C gp120/ MF59 ...................................................................... 35 Canarypox vector encoding HIV1 clade C gp120, clade B gp41, Gag, and protease + protein boost comprising two clade C Env proteins (TV1.Cgp120 and 1086.Cgp120) ............................................. 35 NCT02968849 (HVTN 702) ................................................................................................................. 35 NIAID/HVTN/Bill & Melinda Gates Foundation/South African Medical Research Council/Sanofi Pasteur/ GlaxoSmithKline .................................................................................................................... 35 Phase IIb/ III ......................................................................................................................................... 35 Ad26.Mos4.HIV, clade C gp140/alum .................................................................................................. 35 Ad26 vectors encoding four mosaic Env, Gag, and Pol antigens (Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, Ad26.Mos1. Env, Ad26.Mos2S.Env) Clade C gp140 protein ............................ 35 NCT03060629 (HPX2008/ HVTN 705) ................................................................................................ 35 Janssen Vaccines & Prevention B.V. .................................................................................................. 35 Phase IIb .............................................................................................................................................. 35 HIV DNA-rTV ....................................................................................................................................... 35 DNA prime and replicationcompetent Tiantan vaccinia virus vector boost encoding Gag, Pol, and Env proteins from HIV-1 CN54 ................................................................................................................... 35 ChiCTR1900021422 ............................................................................................................................ 35 Beijing Youan Hospital, Capital Medical University/Center for STD/AIDS Prevention, and Control of China CDC/Beijing Bioproducts Research Institute Company, Ltd.
    • Phase IIa
  • Table 4. Drugs Going Generic in 2020-2024
  • Table 5. CDMO PE Buyouts
  • Table 6. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 , Product Type (US$ million, AGR %)
  • Table 7. Global Monoclonal antibodies Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 8. Insulin Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 9. Global Cytokines Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 10. Global Vaccines Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 11. Global Blood factors Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 12. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
  • Table 13. U.S. Perspective on the Highest-Selling Drugs in 2018
  • Table 14. Cancer Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 15. Diabetes Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 16. Cardiovascular diseases Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 17. CNS Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 18. Infectious Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 19. Others Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 20. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
  • Table 21. Small Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 22. Large Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 23. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
  • Table 24. Bottles Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 25. Ampoules Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 26. Vials Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 27. Prefilled Syringe Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 28. Bags Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Table 29. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million, AGR %)
  • Table 30. The North America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
  • Table 31. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
  • Table 32. The North American CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
  • Table 33. U.S. CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Table 34. Canada CMO of Sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Table 35. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million, AGR %)
  • Table 36. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
  • Table 37. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
  • Table 38. Europe CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030, by Container (US$ million, AGR %)
  • Table 39. Germany CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 40. France CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 41. UK CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 42. Italy CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 43. Spain CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 44. Rest of Europe CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 45. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million, AGR %)
  • Table 46. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
  • Table 47. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
  • Table 48. Asia Pacific CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
  • Table 49. China CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 50. Japan CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 51. India CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 52. Rest of APAC CMO of sterile injectable Forecast (US$ million, AGR %)
  • Table 53. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million, AGR %)
  • Table 54. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
  • Table 55. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
  • Table 56. Latin America CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
  • Table 57. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million, AGR %)
  • Table 58. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million, AGR %)
  • Table 59. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Molecule (US$ million, AGR %)
  • Table 60. Middle East & Africa CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million, AGR %)
  • Table 61. Jubilant Life Sciences Limited Company Overview
  • Table 62. Boehringer Ingelheim company overview
  • Table 63. Pfizer CentreOne company overview
  • Table 64. Baxter Biopharma Solutions company overview
  • Table 65. Recipharm AB company overview
  • Table 66. Lonza company overview
  • Table 67. Famar Health Care Services company overview
  • Table 68. Famar Health Care Services Total Company Sales 2017
  • Table 69. Patheon, Inc Patheon, Inc company overview
  • Table 70. Catalent, Inc company overview
  • Table 71. Almac Group company overview
  • Table 72. Almac Group Total Company Sales 2018
  • Table 73. Evonik Industries AG company overview
  • Table 74. Siegfried Holding AG company overview
  • Table 75. Consort Medical, Plc.company overview
  • Table 76. Jubilant Life Sciences Limited company overview
  • Table 77. Grifols SA company overview

List of Figures

  • Figure 1. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR%)
  • Figure 2. Objectives and Relationship of Customer and CMO
  • Figure 3. CMO of sterile injectable Segmentation
  • Figure 4. CMO of sterile injectable DRO
  • Figure 5. Worldwide Sales at Risk from Patent Expiration (2019-2024)
  • Figure 6. Top 10 Therapy Areas in 2024, Market Share & Sales Growth
  • Figure 7. Survey of U.S. Based Companies: Destination for International Outsourcing "Strong Likelihood" or "Likelihood" for the Next 5 Years
  • Figure 1. CMO of Sterile Injectable Drugs Market Porter's Five Forces
  • Figure 2. CMO of Sterile Injectable Drugs Market by Product Type
  • Figure 3. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million)
  • Figure 4. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (%)
  • Figure 5. Global Monoclonal antibodies Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 6. Insulin Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 7. Global Cytokines Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 8. Global Vaccines Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 9. Global Blood Factors Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 10. CMO of Sterile Injectable Drugs Market by Application
  • Figure 11. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
  • Figure 12. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
  • Figure 13. Cancer Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 14. Diabetes Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 15. Cardiovascular diseases Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 16. CNS Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 17. Infectious Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 18. Others Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 19. CMO of Sterile Injectable Drugs Market by Molecule
  • Figure 20. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
  • Figure 21. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
  • Figure 22. Small Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 23. Large Molecule Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 24. CMO of Sterile Injectable Drugs Market by Container
  • Figure 25. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)
  • Figure 26. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (%)
  • Figure 27. Bottles Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 28. Ampoules Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 29. Vials Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 30. Prefilled Syringe Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 31. Bags Revenue Forecast 2020-2030 (US$ million, AGR %)
  • Figure 32. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR%)
  • Figure 33. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million)
  • Figure 34. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (%)
  • Figure 35. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
  • Figure 36. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
  • Figure 37. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
  • Figure 38. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
  • Figure 39. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)
  • Figure 40. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (%)
  • Figure 8. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (%)
  • Figure 9. The North America CMO of Sterile Injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 10. U.S. CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 11. Canada CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 12. Europe CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 13. Germany CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 14. France CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 15. UK CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 16. Italy CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 17. Spain CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 18. Rest of Europe CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 19. Asia Pacific CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 20. China CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 21. Japan CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 22. India CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 23. Rest of APAC CMO of sterile injectable Forecast (US$ million, AGR %)
  • Figure 24. Latin America CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 25. Middle East & Africa CMO of sterile injectable Forecast 2020-2030 (US$ million, AGR %)
  • Figure 26. Jubilant Life Sciences Limited Total Company Sales 2016-2019
  • Figure 27. Products / Services
  • Figure 28. Mergers & Acquisitions (M&A) Activity
  • Figure 29. Boehringer Ingelheim Total Company Sales 2016-2018
  • Figure 30. Products / Services
  • Figure 31. Mergers & Acquisitions (M&A) Activity
  • Figure 32. Pfizer CentreOne Total Company Sales 2016-2019
  • Figure 33. Products / Services
  • Figure 34. Mergers & Acquisitions (M&A) Activity
  • Figure 35. Baxter Biopharma Solutions Total Company Sales 2016-2019
  • Figure 36. Products / Services
  • Figure 37. Mergers & Acquisitions (M&A) Activity
  • Figure 38. Recipharm AB Total Company Sales 2016-2018
  • Figure 39. Products / Services
  • Figure 40. Mergers & Acquisitions (M&A) Activity
  • Figure 41. Lonza Total Company Sales 2016-2019
  • Figure 42. Products / Services
  • Figure 43. Mergers & Acquisitions (M&A) Activity
  • Figure 44. Products / Services
  • Figure 45. Mergers & Acquisitions (M&A) Activity
  • Figure 46. Patheon, Inc Total Company Sales 2016-2018
  • Figure 47. Products / Services
  • Figure 48. Mergers & Acquisitions (M&A) Activity
  • Figure 49. Catalent, Inc. Total Company Sales 2016-2019
  • Figure 50. Products / Services
  • Figure 51. Mergers & Acquisitions (M&A) Activity
  • Figure 52. Products / Services
  • Figure 53. Mergers & Acquisitions (M&A) Activity
  • Figure 54. Evonik Industries AG Total Company Sales 2016-2019
  • Figure 55. Products / Services
  • Figure 56. Mergers & Acquisitions (M&A) Activity
  • Figure 57. Siegfried Holding AG Total Company Sales 2016-2019
  • Figure 58. Products / Services
  • Figure 59. Mergers & Acquisitions (M&A) Activity
  • Figure 60. Consort Medical, Plc. Total Company Sales 2016-2019
  • Figure 61. Products / Services
  • Figure 62. Mergers & Acquisitions (M&A) Activity
  • Figure 63. Products / Services
  • Figure 64. Grifols SA Total Company Sales 2016-2019
  • Figure 65. Products / Services
  • Figure 66. Mergers & Acquisitions (M&A) Activity
  • Figure 67. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 (US$ million, AGR%)
  • Figure 68. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (US$ million)
  • Figure 69. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Product Type (%)
  • Figure 70. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
  • Figure 71. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
  • Figure 72. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (US$ million)
  • Figure 73. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Application (%)
  • Figure 74. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (US$ million)
  • Figure 75. Global CMO of Sterile Injectable Drugs Revenue Forecast 2020-2030 Container (%)